Special Issue

Recent Advances in Understanding Epstein-Barr Virus

Message from the Guest Editors

The Epstein-Barr virus (EBV) is a human gammaherpesvirus and more than 90% of population is infected with the virus. EBV infects with oropharyngeal naïve B lymphocytes through saliva then spread to the adjacent B lymphocytes and epithelial cells. Immunological maturation of infected host divides initial infections to asymptomatic infection in infancy and infectious mononucleosis in adolescence. The initial productive lytic infection will shift to persistent latent infection, where limited viral transcripts are expressed to support persistent infection. In most of the cases. EBV associates with the infected person without any symptoms during the person's life. Primarily resting memory B lymphocytes in peripheral blood provide a permanent reservoir for the virus. However, EBV sometimes shifts from latent to lytic infection in association with local or systemic immunological suppressions. The life long persistence and regional activation may induce oncogenic activation of infected cells in some persons.

Guest Editors

Prof. Dr. Hironori Yoshiyama Department of Microbiology, Shimane University Faculty of Medicine, Shimane 693-8501, Japan

Prof. Teru Kanda Department of Microbiology, Faculty of Medicine, Tohoku Medical Pharmaceutical University, Sendai, Japan

Deadline for manuscript submissions

closed (31 March 2019)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/17463

Microorganisms Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 microorganisms@mdpi.com

mdpi.com/journal/ microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



microorganisms



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).